Tirzepatide vs Retatrutide

Both are highly effective GLP-1 medications. Here's how they compare to help you make the right choice.

Not sure? Take the quiz →
T

Tirzepatide

Proven & Affordable

The go-to choice for most people. FDA approved, extensively studied, and our most affordable option.

  • Best for first-timers
  • More safety data available
  • Lower starting cost

From ₱4,500/month

Learn More →
Most Advanced
R

Retatrutide

Maximum Results

The next generation. Triple mechanism for those who want the best possible results or have plateaued on other medications.

  • Highest efficacy in trials
  • Best for plateaus
  • Exclusive in PH

From ₱6,500/month

Learn More →

Detailed Comparison

Feature Tirzepatide Retatrutide
Mechanism Dual agonist (GLP-1 + GIP) Triple agonist (GLP-1 + GIP + Glucagon)
Avg. Weight Loss 15-21% 17-24%
Trial Duration 72 weeks 48 weeks
FDA Status Approved (2022) Phase 3 trials
Starting Price ₱4,500/month ₱6,500/month
Dosing Once weekly Once weekly
Safety Data Extensive (millions of users) Limited (trial participants)
PH Availability Multiple providers MetabolixPH exclusive

Which Is Right for You?

Choose Tirzepatide if you:

  • Are new to GLP-1 medications
  • Prefer medications with extensive long-term data
  • Want an affordable entry point
  • Have moderate weight loss goals (10-20%)
  • Prefer a steady, gradual approach
Start with Tirzepatide →

Choose Retatrutide if you:

  • Want maximum possible results
  • Have plateaued on other GLP-1s
  • Have significant weight to lose (20+ kg)
  • Want results as fast as safely possible
  • Budget is flexible for best results
Start with Retatrutide →

The Science Explained

Why Does Mechanism Matter?

GLP-1, GIP, and Glucagon are hormones that regulate appetite, blood sugar, and energy expenditure. More receptors targeted = more pathways to weight loss. Retatrutide's additional glucagon activity is thought to increase calorie burning, which may explain its superior results in trials.

Clinical Trial Comparison

Tirzepatide (SURMOUNT-1)

20.9%

weight loss at 72 weeks

Retatrutide (Phase 2)

24.2%

weight loss at 48 weeks

Note: Different trial durations make direct comparison imperfect. Phase 3 results for Retatrutide expected in 2025.

Still Not Sure?

Take our 2-minute quiz and get a personalized recommendation based on your goals, health profile, and preferences.

Get Your Recommendation →